CoreWeave, a specialized cloud computing company, is trying to tap insurance companies for financing to lower the cost of the credit it needs to buy AI chips, the Financial Times reported on October 14.
The NVIDIA-backed company wants to diversify its sources of financing as demand for AI computing grows. As of mid-to-late 2026, CoreWeave’s total outstanding debt reached approximately $35.1 billion, reflecting the heavy reliance on debt financing to fuel its AI hardware expansion against its $104 billion+ revenue backlog.
Brannin McBee, CoreWeave’s co-founder and head of financing, told the FT that insurers’ pools of capital are effectively “unlimited.”
He said CoreWeave is seeking investment-grade ratings for more of its chip-backed debt and, eventually, for the company itself. Insurers can hold far more investment-grade paper than speculative debt, so higher ratings would open the door to that money.
Earlier this year, CoreWeave managed to secure an $8.5 billion loan with the help of NVIDIA chips and its long-term contract with Meta.
In addition to that, CoreWeave would like to start attracting the insurance fraternity to invest in loans tied to lower credit-rated clients, including ones related to AI labs. This may help the company to find new sources of financing and cut borrowing costs.
CoreWeave now wants to extend the approach to debt backed by contracts with lower-rated customers, including AI labs. McBee said those loans are not yet ready for insurers. He added that planned stock market listings by large AI labs could help broaden acceptance of that debt among insurance investors.
CoreWeave has raised more than $35 billion this year through chip-backed loans, high-yield bonds, convertible bonds and share sales. That growth has left it with about $52 billion in debt and lease obligations as of the end of June.
The financing strategy also highlights the growing financial risks associated with the AI infrastructure boom.
Also Read: NVIDIA Pledges $250 million in Compute Access to Strengthen UKs’ Agentic Safety Research






